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Abstract 
Background: Following the adoption of the Global Action Plan for the Prevention and Control of NCDs 2013–2020, 
an update to the Appendix 3 of the action plan was requested by Member States in 2016, endorsed by the Seventieth 
World Health Assembly in May 2017 and provides a list of recommended NCD interventions. The main contribution of 
this paper is to present results of analyses identifying how decision makers can achieve maximum health gain using 
the cancer interventions listed in the Appendix 3. We also present methods used to calculate new WHO-CHOICE 
cost-effectiveness results for breast cancer, cervical cancer, and colorectal cancer in Southeast Asia and eastern sub-
Saharan Africa.
Methods: We used “Generalized Cost-Effectiveness Analysis” for our analysis which uses a hypothetical null reference 
case, where the impacts of all current interventions are removed, in order to identify the optimal package of interven-
tions. All health system costs, regardless of payer, were included. Health outcomes are reported as the gain in healthy 
life years due to a specific intervention scenario and were estimated using a deterministic state-transition cohort 
simulation (Markov model).
Results: Vaccination against human papillomavirus (two doses) for 9–13-year-old girls (in eastern sub-Saharan Africa) 
and HPV vaccination combined with prevention of cervical cancer by screening of women aged 30–49 years through 
visual inspection with acetic acid linked with timely treatment of pre-cancerous lesions (in Southeast Asia) were found 
to be the most cost effective interventions. For breast cancer, in both regions the treatment of breast cancer, stages 
I and II, with surgery ± systemic therapy, at 95% coverage, was found to be the most cost-effective intervention. For 
colorectal cancer, treatment of colorectal cancer, stages I and II, with surgery ± chemotherapy and radiotherapy, at 
95% coverage, was found to be the most cost-effective intervention.
Conclusion: The results demonstrate that cancer prevention and control interventions are cost-effective and can be 
implemented through a step-wise approach to achieve maximum health benefits. As the global community moves 
toward universal health coverage, this analysis can support decision makers in identifying a core package of cancer 
services, ensuring treatment and palliative care for all.
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Background
Although not specifically mentioned in the millennium 
development goals (MDGs), cancer is now addressed in 
target 3.4 of the sustainable development goals (SDGs), 
which aims to reduce premature mortality related to 
noncommunicable diseases (NCDs). Cancer is one of the 
main causes of morbidity and mortality worldwide, with 
the incidence of new cases expected to rise by 70% in the 
next two decades [1]. Between 2000 and 2015, cancer 
deaths globally increased from 7 million to 8.8 million 
deaths each year, accounting for 1 in 6 of all deaths glob-
ally and the largest relative increase has been in low- and 
middle-income countries, where health systems are least 
prepared to manage the cancer burden [2]. While com-
municable disease deaths have decreased 26% between 
2000 and 2015, deaths from cancer have increased 26%, 
with a significant increased proportion of cancer-related 
deaths occurring in Asia and Africa [2, 3]. Cervical can-
cer and breast cancer are the leading causes of cancer-
related death among women in the sub-Saharan Africa 
region, resulting in, respectively, 23.2% and 19.3% [3] of 
total cancer deaths; colorectal cancer is one of the most 
common causes of cancer-related death for both sexes 
worldwide [3]. The total annual economic costs of can-
cer globally was estimated at approximately US$ 1.16 tril-
lion in 2010 and has continued to rise, threatening health 
budgets and economies at all income levels and also caus-
ing financial catastrophe for individuals and families [3].
Following the adoption of the Global Action Plan 
for the Prevention and Control of NCDs 2013–2020 in 
2013 [4], an update to Appendix 3 of the action plan was 
requested by the Member States in 2016 [5]. The update, 
which provides a list of recommended NCD interven-
tions, was endorsed by the Seventieth World Health 
Assembly in May 2017. These priority NCD interven-
tions, if implemented to scale, would enable countries to 
make significant progress to reduce by 25% the number 
of the NCD-related premature death by 2025 [6].
To achieve these targets and those specified in the 
United Nations Agenda for Sustainable Development, 
cancer screening programs need to become more sys-
tematic and reach a more significant proportion of their 
target populations in Southeast Asia and eastern sub-
Saharan Africa. Data from the WHO Country Capacity 
Survey 2015 found that countries in WHO South-East 
Asia (SEAR) and Africa regions (AFR) were the least 
likely among WHO Regions to have a breast screening 
program with 64% and 57% availability respectively. How-
ever, the majority of screening programs reached less 
than 10% coverage in these regions. Human papilloma-
virus (HPV) vaccination was available in approximately 
50% of countries in AFR and almost 20% in SEAR, simi-
larly with the majority reaching less than 10% coverage. 
Cancer centres or cancer departments were available 
in approximately 55% of countries in SEAR and 30% in 
AFR. Treatment, including cancer surgery and subsidized 
chemotherapy, and palliative care services were also gen-
erally unavailable to the majority of countries [7].
The main contribution of this paper is to present 
results of analyses used to identify how decision makers 
can achieve maximum health gain using the cancer inter-
ventions in Appendix 3 of the global action plan. We also 
present methods used to calculate new WHO-CHOICE 
cost-effectiveness results for breast cancer, cervical can-
cer, and colorectal cancer. The “expansion paths” we 
present are a proposed sequence in which interventions 
could be adopted to achieve the maximum health gain. 
The order in which each intervention or combination of 
interventions appears on the line is based on the incre-
mental costs and effectiveness of each intervention com-
pared to the last one on the line [8].
Methods
We used Generalized Cost-Effectiveness Analysis 
(GCEA) for our analysis, which is an approach recom-
mended by WHO-CHOICE and details of which have 
been published previously [8–10]. In this paper, we 
describe the methods related to breast cancer, cervical 
cancer, and colorectal cancer.
We did not analyze all possible combinations of inter-
ventions for these three cancers, an approach which has 
been previously studied [11]. Instead, we emphasize a 
package of interventions relevant to a comprehensive 
cancer control programme. A “comprehensive cancer 
control approach” consists of prevention, early diag-
nosis and screening linked to treatment, palliative care, 
and survivorship care [12]. We focus moreover on those 
aspects of comprehensive cancer control that are gener-
alizable to all resource settings. Furthermore, based on 
previous work on cancer [13, 14], the use of an approach 
based on comprehensive cancer control has been found 
to be justified on grounds of cost effectiveness.
We considered aspects of the expansion path that take 
into account specific programmatic concerns. This means 
that, if a particular technology appears on the expansion 
path at a certain level of coverage, then for the next step, 
we considered the most cost effective interventions that 
included this particular technology at the same or higher 
coverage, since a decision maker would likely not wish to 
bring a particular intervention up to scale only to replace 
it with a competing technology when higher levels of 
resources are available.
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Our analysis is restricted to Southeast Asia and east-
ern sub-Saharan Africa [15] and uses epidemiological 
and cost data for a base year of 2010. These two regions 
were selected as they are geographically and epidemio-
logically diverse regions which will provide differing 
examples of cost-effectiveness results and, we predicted, 
would have different findings. These regions are a WHO-
CHOICE level feature across 20 diseases/risk factors. A 
generic approach is required for standardization. The 
results are intended to be indicative examples, rather 
than prescriptive packages for countries to implement. 
Health outcomes are reported as the gain in healthy life 
years (HLYs) and are estimated using a dynamic simu-
lation model in the Spectrum software. HLYs are pre-
sented both undiscounted and discounted at 3% per 
annum [8]. Disability weights (DWs) were obtained from 
the Global Burden of Disease (GBD) study 2010 [16]. All 
health system costs required to deliver the intervention 
are included, regardless of payer. Costs include patient-
level delivery costs as well as programme-level (i.e. over-
head) costs [17]. A 3% per annum discount is applied to 
costs in all scenarios [8]. Programmes are considered to 
be implemented for 100 years. Each individual and com-
bined intervention is evaluated at 50%, 80% and 95% 
coverage levels [17].
Impact modelling
Interventions
This paper analyses 14 individual and combination inter-
ventions: 9 for cervical cancer, 3 for breast cancer, and 2 
for colorectal cancer.
These interventions are listed in Table  1. All inter-
ventions are first compared to the “null,” a hypothetical 
scenario where the effects of all currently implemented 
interventions are removed. Following the definition of 
the null, the marginal effects and costs of each interven-
tion or combination are evaluated.
Interventions are based on WHO Guidance for cervi-
cal cancer [18], for breast cancer [6, 14, 19, 20] and for 
colorectal cancer [14, 19–21]. These guidelines empha-
size comprehensive cancer control including diagnosis, 
staging, multi-modality treatment, survivorship care and 
palliative care.
Estimation of HLYs
Health outcomes were estimated using a determinis-
tic state-transition cohort simulation (Markov model). 
In this type of simulation, healthy stages and disease 
stages, distributed by age, are modelled as the exhaus-
tive and mutually exclusive states of a Markov model, 
i.e. at any cross-sectional point in time, all persons in 
Table 1 Interventions included in the analysis
Disease Label Interventions [22]
Cervical cancer C1a Vaccination against human papillomavirus (two doses) of 9–13-year-old girls
C1b Prevention of cervical cancer by screening women aged 30–49 through visual inspection with acetic acid linked with timely 
treatment of pre-cancerous lesions
C1c Prevention of cervical cancer by screening women aged 30–49 through Pap smear (cervical cytology) every 3–5 years linked 
with timely treatment of pre-cancerous lesions
C1d Prevention of cervical cancer by screening women aged 30–49 through human papillomavirus test every 5 years linked with 
timely treatment of pre-cancerous lesions
C1e Vaccination against human papillomavirus (two doses) of 9–13-year-old girls and prevention of cervical cancer by screening 
women aged 30–49 through visual inspection with acetic acid linked with timely treatment of pre-cancerous lesions
C1f Vaccination against human papillomavirus (two doses) of 9–13-year-old girls and prevention of cervical cancer by screening 
women aged 30–49 through Pap smear (cervical cytology) every 3–5 years linked with timely treatment of pre-cancerous 
lesions
C1g Vaccination against human papillomavirus (two doses) of 9–13-year-old girls and Prevention of cervical cancer by screening 
women aged 30–49 through human papillomavirus test every 5 years linked with timely treatment of pre-cancerous 
lesions
C1h Treatment of cervical cancer stages I and II with either surgery or radiotherapy ± chemotherapy
C1i Basic palliative care for cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essen-
tial supportive medicines
Breast cancer C2a Treatment of breast cancer stages I and II with surgery ± systemic therapy
C2b Screening with mammography (once every 2 years for women aged 50–69 years) linked with timely diagnosis and treat-
ment of breast cancer
C2c Basic palliative care for cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essen-
tial supportive medicines
Colorectal cancer C3a Treatment of colorectal cancer stages I and II with surgery ± chemotherapy and radiotherapy
C3b Basic palliative care for cancer: home-based and hospital care with multi-disciplinary team and access to opiates and essen-
tial supportive medicines
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the population belong to one and only one of the states. 
As persons age, they transition between states based on 
state-specific transition rates. They can either remain in 
the healthy state, or transition from healthy to the ini-
tial disease state, representing disease onset, and then 
transition between subsequent disease states, represent-
ing either progression to an advanced state of disease or 
regression to a lower disease state or back to the healthy 
state. Regression to healthy state is modelled only for 
pre-cancerous states. By representing preclinical and 
clinical disease stages as separate states, diagnoses are 
modelled through transitions from preclinical to clinical 
states. Persons can transition to mortality from any state, 
at which point they leave the model. To model the impact 
of disease and treatment, different rates are used for 
transitioning to mortality, e.g. higher rates are applied to 
more advanced stages of disease to represent the reduced 
effectiveness of treatment. A brief outline of the state 
transitions specific to each type of cancer are discussed 
below, and detailed flow diagrams are presented in Addi-
tional file 1. The model is discussed in more detail in [23].
In the absence of an intervention, transitions are based 
on natural rates of progression or regression. With an 
intervention, rates of transitions are modified, e.g. the 
rates from healthy to HPV state are decreased to repre-
sent the effectiveness of vaccination, or the rates from 
preclinical to clinical states are increased, such that more 
persons are diagnosed in early stages of disease to rep-
resent effective screening. The health outcomes of inter-
ventions are measured as a relative increase in healthy 
life years lived in an intervention scenario compared to 
no intervention. Healthy life years are calculated as the 
sum of person-time in all states (except mortality) after 
discounting for disability specific to each state (see “Dis-
ability weights”).
Cervical cancer The vast majority of cervical cancer 
cases originate as human papillomavirus (HPV) infection, 
a sexually transmitted disease. Therefore, the cervical can-
cer state-transition model consisted of three components: 
HPV transmission, pre-cancerous HPV progression and 
regression, and cervical cancer progression. HPV sub-
types were categorized into three groups: (i) HPV 16/18 
(which contributes to an estimated 70% [24] of all cervi-
cal cancers), (ii) HPV high-risk (all HPV types other than 
16/18 that are at high-risk of progressing to cancer), and 
(iii) HPV low-risk (all other types that have a low-risk of 
progressing to cancer). Co-infection with multiple sub-
types was not modelled.
It was assumed that women in the healthy state can 
become infected with one of the three HPV catego-
ries through sexual contact with an infected partner. 
Therefore, the rates of transition from healthy to HPV 
states were determined dynamically through a trans-
mission model. In the pre-cancerous part of the model, 
persons in the HPV+ state could progress to cervi-
cal intra-epithelial neoplasia (CIN), subsequently to a 
low-grade dysplasia CIN-1, and then advance to CIN-
2-3. Persons in CIN stages could naturally regress in 
disease stage and have HPV clearance, or could regress 
to HPV upon screening and treatment. Upon regres-
sion, there was short-term immunity to HPV before 
transitioning to healthy state that re-exposed persons 
to infection. From CIN-2-3, persons could progress to 
invasive cancer, first to carcinoma in  situ (CIS), and 
further to states I, II, III, and IV. From any of these 
states, persons could transition from pre-clinical to 
clinical states through diagnosis based on symptoms 
or through screening. In men, we did not model can-
cers related to HPV, but only modelled HPV infection, 
transmission and natural regression. Detailed flow dia-
grams of the state transitions are presented in Addi-
tional file 1.
Breast cancer We assumed that breast cancer initiated 
directly as carcinoma in  situ (CIS), i.e., women could 
transition from healthy to CIS then progress to invasive 
carcinoma stages I, II, III, and IV. From any of these dis-
ease states, persons could transition from pre-clinical to 
clinical states through diagnosis based on symptoms or 
through screening.
Colorectal cancer We assumed that about 77% of 
colorectal cancers originate as pre-cancerous polyps 
and the remaining 23% originate directly as carcinoma 
in  situ (CIS) [25, 26]. We have divided the pre-cancer-
ous states into three different sizes of polyps (≤ 5  mm, 
6–9 mm, ≥ 10 mm) because of the variation in effective-
ness of treatment by polyp size [27]. Upon transition 
to CIS, disease progresses through invasive carcinoma 
stages I, II, III, and IV. From any of these states, persons 
can transition from pre-clinical to clinical states through 
diagnosis based on symptoms or through screening.
Data sources for state‑transition rates
We assumed that natural rates of transition from healthy 
to first stage of disease and from preclinical to clini-
cal states, i.e., in the absence of a controlled interven-
tion program, were specific to the population. These 
population-specific parameters were estimated using a 
newly developed Markov-process methodology that is 
described in elsewhere [23] and summarized in Addi-
tional file 1. We assumed that rates of natural progression 
and regression between disease states are specific to the 
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cancer but do not vary by population. We extracted these 
parameters from the literature (see Additional file 1).
Each major cancer group (i.e., breast, cervical and 
colorectal) and each stage of disease has unique values 
for transition parameters to account for variations in 
the tumor biology and progression of cancer. It is likely 
that there are also differences in the natural history and 
tumor biology between the different molecular subtypes 
within each of these major cancer groups. Currently, the 
published studies in LMIC from which parameters are 
generated have not generally distinguished between these 
molecular subtypes. However, the parameters of the 
model do allow for greater specificity that can be used 
as more data on the diagnosis and treatment of cancer 
subtypes becomes available—for example, the diagnostic 
rates and impact of trastuzumab for HER2+ breast can-
cer in LMIC, which does have a distinct natural history 
and impact of this particular treatment strategy.
Intervention effect sizes
Disability weights Disability weights (DWs) for each 
health state were drawn from the disability weight study 
of the Global Burden of Disease 2010 [16] and can be 
found in Additional file 2, Table S2.
GBD provides DWs for the following general cancer 
stages: “cancer: diagnosis and primary therapy”, “Cancer: 
metastatic”, “terminal phase: with medication (for can-
cers, end-stage kidney or liver disease)”, “terminal phase: 
without medication (for cancers, end-stage kidney or 
liver disease)”, as well as “mastectomy” and “stoma” can-
cer-specific stages/states.
For all three cancer types, we obtained DWs for all pre-
terminal cancer phases without treatment, by inflating 
the “cancer: diagnosis and primary therapy” DW estimate 
by the ratio between the two DW estimates provided for 
terminal cancer without treatment. For the terminal can-
cer stage of each cancer type, we used the GBD estimate 
directly.
For the DWs for cancer with treatment, for the termi-
nal cancer stage of each cancer type, we used the GBD 
estimate directly. For the pre-terminal cancer stages 
we followed a disease-specific approach, as described 
following.
Cervical cancer For the early stages (0–II) we used the 
DW for “cancer: diagnosis and primary therapy” and 
applied a correction for the percentage of cases in the first 
year of treatment only. For stage III we did not apply a 
correction.
Breast cancer For early stages (I and II) we used a 
weighted average DW for “cancer: diagnosis and primary 
therapy” and “mastectomy”, and applied the DW to the 
percentage of cases in the first year of treatment only. For 
stage III we used “cancer: diagnosis and primary therapy”, 
and we applied the DW to the percentage of cases in the 
first year of treatment in that stage.
Colorectal cancer We used a weighted average DW for 
“cancer: diagnosis and primary therapy” and “stoma” for 
the estimated 5% of patients who would require a stoma, 
and adjusted the part corresponding to “cancer: diagnosis 
and primary therapy” for the percentage of cases in the 
first year of treatment in that stage only, except for stage 
III for which we did not apply this correction.
Incidence For all three cancers, incidence estimates and 
age at diagnosis are sourced from GLOBOCAN [21].
For cervical cancer, estimates of HPV distribution by 
type are taken from [28–30]. Transition rates from dys-
plasia (CIN) to carcinoma are taken from [31].
All effect sizes can be found in the Additional file 2.
Intervention costing
We followed a standardized framework developed for 
WHO-CHOICE to cost all the interventions. We used 
an “ingredients based” approach, whereby each input 
required for the intervention is identified and valued. 
We have included costs incurred at the point of deliv-
ery such as drugs and supplies, and health facility visits 
(including health workforce costs), as well as program-
matic costs such as administration, monitoring and 
evaluation, supervision, training [17]. Programmatic 
costs for cancer screening include administrative costs, 
quality assurance and monitoring and evaluation, esti-
mated at approximately 20% of total costs [32]. Screen-
ing programme costs include follow-up diagnostic tests 
for false positive screening results. All intervention costs 
are calculated assuming that the health system capacity is 
available to support the intervention. Lists of consuma-
bles were identified from WHO Priority Medical Devices 
in Cancer Management 2017 [33]. Consumables required 
include those needed for treatment-related complications 
and surveillance after treatment completion. Systemic 
therapy treatment regimens were taken from WHO List 
of Essential Medicines [34]. Prices were taken from the 
MSH drug price database as median buyer price [35] and 
from the WHO-CHOICE price database [17]. Costs in 
all scenarios were discounted at 3% per annum. Costs are 
reported in 2010 International dollars. Costing assump-
tions can be found in Additional file 2.
Results
Costs, HLYs gained, and the cost effectiveness associ-
ated with each intervention are presented in Tables 2 and 
Table  3. These tables present only the most cost-effective 
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Table 2 Costs, effects and incremental cost-effectiveness of cancer interventions in Southeast Asia
Label Description 
of the intervention
Pop° 
coverage 
(%)
Costs per 10 million 
population (million I$ 
2010)
HLY per 10 million 
population 
(undiscounted)
Average cost-
effectiveness ratio 
(ACER)
Incremental cost-
effectiveness ratio 
(ICER)
CVC_C1e Vaccination against 
human papilloma-
virus (two doses) of 
9–13-year-old girls and 
prevention of cervical 
cancer by screening 
women aged 30–49 
through visual inspec-
tion with acetic acid 
linked with timely treat-
ment of pre-cancerous 
lesions
50 396 4,541,842 87 87
CRC_C3a Treatment of colorectal 
cancer stages I and II 
with surgery ± chemo-
therapy and radio-
therapy
95 207 870,417 238 238
BRC_C2a Treatment of breast 
cancer stages I and II 
with surgery ± systemic 
therapy
95 206 816,200 252 252
CVC_C1e Vaccination against 
human papilloma-
virus (two doses) of 
9–13-year-old girls and 
prevention of cervical 
cancer by screening 
women aged 30–49 
through visual inspec-
tion with acetic acid 
linked with timely treat-
ment of pre-cancerous 
lesions
80 549 5,106,391 108 272
CVC_C1e Vaccination against 
human papilloma-
virus (two doses) of 
9–13-year-old girls and 
prevention of cervical 
cancer by screening 
women aged 30–49 
through visual inspec-
tion with acetic acid 
linked with timely treat-
ment of pre-cancerous 
lesions
95 626 5,262,580 119 491
BRC_C2b Screening with mam-
mography (once every 
2 years for women 
aged 50–69 years) 
linked with timely diag-
nosis and treatment of 
breast cancer
95 1056 1,627,782 649 1048
BRC_C2c Basic palliative care for 
breast cancer: home-
based and hospital care 
with multi-disciplinary 
team and access to 
opiates and essential 
supportive medicines
95 193 22,877 8434 8434
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interventions on the sectoral expansion path for all three 
cancers. Interventions that are “dominated” i.e. are more 
costly or less effective, are presented in cancer-specific 
tables (see Additional file 2).
For cervical cancer, vaccination against human papil-
lomavirus (two doses) of 9–13-year-old girls combined 
with prevention of cervical cancer by screening women 
aged 30–49 through visual inspection with acetic acid 
linked with timely treatment of pre-cancerous lesions 
(CVC_C1e) at 50% coverage is the most cost-effective 
intervention in Southeast Asia, with an incremental cost-
effectiveness of I$ 87 per HLY gained. At full coverage 
(95%), this combination intervention produces the high-
est effectiveness among all cervical cancer interventions. 
In eastern sub-Saharan Africa, vaccination against human 
papillomavirus (two doses) of 9–13-year-old girls (CVC_
C1a) as an individual intervention, at 50% coverage is the 
most cost-effective intervention for cervical cancer, with 
an Incremental Cost-Effectiveness Ratio (ICER) of I$ 28 
per HLY gained. For maximum health gain, this interven-
tion then has to be progressively brought up to 95% cov-
erage and combined with prevention of cervical cancer, 
by screening women aged 30–49 through visual inspec-
tion with acetic acid linked with timely treatment of pre-
cancerous lesions (CVC_C1e).
For breast cancer, for both regions, treatment of breast 
cancer stages I and II with surgery ± systemic therapy 
(BRC_C2a) at 95% coverage is the most cost-effective 
intervention with an ICER of I$ 252 per HLY gained in 
Southeast Asia and I$ 113 per HLY gained in eastern 
sub-Saharan Africa. Screening with mammography (once 
every 2  years for women aged 50–69  years) linked with 
timely diagnosis and treatment (BRC_C2b) is less cost-
effective, since mammography is a high-resource use 
technology. In addition, mammography requires a robust 
health infrastructure for a country to be able to sustain 
an organized population-based screening programme 
[36].
For colorectal cancer, for both regions, treatment of 
colorectal cancer, stages I and II, with surgery ± chemo-
therapy and radiotherapy (CRC_C3a) at 95% coverage is 
cost effective at I$ 238 per HLY gained in southeast Asia, 
and I$ 217 per HLY gained in eastern sub-Saharan Africa.
Overall, cervical cancer interventions are the most 
cost effective strategies among the studied interventions 
against cancer. Their favourable cost-effectiveness ratio 
arises from effective primary and/or secondary preventa-
tive strategies that effectively reduce the burden of dis-
ease at a low cost.
For all three cancers, basic palliative care is an essential 
element in cancer control that should be added at 95% 
coverage for optimal implementation.
Figures  1 and 2 show the expansion path a decision 
maker would follow to achieve the maximum health gain 
in respectively, Southeast Asia and eastern sub-Saharan 
Africa.  
If, with enough resources, all the interventions on 
the expansion path can be implemented, the budgetary 
allocation at full coverage across each of the three can-
cers would be as follows: in Southeast Asia: breast can-
cer, 56%; cervical cancer, 30%; colorectal cancer, 14%; in 
Eastern sub-Saharan Africa: Breast Cancer, 48%; Cervical 
Cancer, 45%; Colorectal Cancer, 7% (Table 4).
Discussion
Principal findings
The burden of disease and economic impact of cancer 
are significant and increasing. Effective cancer control 
CVC cervical cancer, BRC breast cancer, CRC colorectal cancer
Table 2 (continued)
Label Description 
of the intervention
Pop° 
coverage 
(%)
Costs per 10 million 
population (million I$ 
2010)
HLY per 10 million 
population 
(undiscounted)
Average cost-
effectiveness ratio 
(ACER)
Incremental cost-
effectiveness ratio 
(ICER)
CRC_C3b Basic palliative care for 
colorectal cancer: 
home-based and hos-
pital care with multi-
disciplinary team and 
access to opiates and 
essential supportive 
medicines
95 158 5944 26,571 26,571
CVC_C1i Basic palliative care for 
cervical cancer: home-
based and hospital care 
with multi-disciplinary 
team and access to 
opiates and essential 
supportive medicines
95 156 5262 29,704 29,704
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Table 3 Costs, effects and incremental cost-effectiveness of cancer interventions in Eastern sub-Saharan Africa
CVC cervical cancer, BRC breast cancer, CRC colorectal cancer
Label Description 
of the intervention
Pop° 
coverage 
(%)
Costs per 10 million 
population (I$ 2010)
HLY per 10 million 
population 
(undiscounted)
Average cost-
effectiveness ratio 
(ACER)
Incremental cost-
effectiveness ratio 
(ICER)
CVC_C1a Vaccination against human 
papillomavirus (two doses) 
of 9–13-year-old girls
50 146 5,215,136 28 28
CVC_C1a Vaccination against human 
papillomavirus (two doses) 
of 9–13-year-old girls
80 190 6,773,262 28 28
CVC_C1e Vaccination against human 
papillomavirus (two doses) 
of 9–13-year-old girls and 
prevention of cervical 
cancer by screening women 
aged 30–49 through visual 
inspection with acetic acid 
linked with timely treatment 
of pre-cancerous lesions
80 1163 30,421,065 38 41
BRC_C2a Treatment of breast cancer 
stages I and II with sur-
gery ± systemic therapy
95 157 1,389,662 113 113
CVC_C1e Vaccination against human 
papillomavirus (two doses) 
of 9–13-year-old girls and 
prevention of cervical 
cancer by screening women 
aged 30–49 through visual 
inspection with acetic acid 
linked with timely treatment 
of pre-cancerous lesions
95 1362 31,554,286 43 175
CRC_C3a Treatment of colorectal 
cancer stages I and II with 
surgery ± chemotherapy 
and radiotherapy
95 136 626,379 217 217
BRC_C2b Screening with mammogra-
phy (once every 2 years for 
women aged 50–69 years) 
linked with timely diagnosis 
and treatment of breast 
cancer
95 1307 2,697,617 485 485
BRC_C2c Basic palliative care for breast 
cancer: home-based and 
hospital care with multi-
disciplinary team and access 
to opiates and essential 
supportive medicines
95 171 56,749 3009 3009
CVC_C1i Basic palliative care for cervical 
cancer: home-based and 
hospital care with multi-
disciplinary team and access 
to opiates and essential 
supportive medicines
95 161 48,488 3316 3316
CRC_C3b Basic palliative care for colo-
rectal cancer: home-based 
and hospital care with multi-
disciplinary team and access 
to opiates and essential 
supportive medicines
95 113 5602 20,117 20,117
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planning requires accurate data for planning, costing 
and implementation. This study assists policy makers in 
obtaining the best value for money for breast, cervical 
and colorectal cancer control by identifying the impact 
and costs of priority cancer control interventions as part 
of a comprehensive programme.
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Fig. 1 Cost effectiveness expansion path for Southeast Asia. Refer to Table 1 for interventions’ labels
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Fig. 2 Cost effectiveness expansion path for Eastern sub-Saharan Africa. Refer to Table 1 for interventions’ labels
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There are four principle findings in this study: (i) can-
cer prevention and control interventions are cost-effec-
tive and can significantly reduce the burden of disease 
globally; (ii) a step-wise approach to implementation that 
considers context-specific expansion paths can be uti-
lized; (iii) interventions for early-stage cancers are gener-
ally more cost-effective than those for late-stage cancers; 
and (iv) palliative care programmes, which should be pri-
oritized since it is considered as human right to health 
and recommended by the World Health Assembly [37–
39], can be implemented at generally low cost.
Cancer and other noncommunicable diseases have 
received low priority, donor support and domestic 
resource allocation in low resource settings [40]. Contrib-
uting factors are the presumed high costs and low health 
impact of cancer interventions. This study highlights that 
cancer interventions are cost-effective and can be imple-
mented in a comprehensive approach, in line with other 
NCD interventions as well as accepted communicable 
disease interventions [41]. Two interventions, in particu-
lar, were found to be highly cost-effective, exceeding an 
average cost-effectiveness ratio (ACER) threshold of less 
than I$ 100 per HLY. These interventions are the pre-
vention of cervical cancer through HPV vaccination and 
the screening and treatment of pre-cancerous lesions. 
Critically, cost-effectiveness also depends on regional 
incidence—cervical cancer interventions are more cost 
effective in eastern sub-Saharan Africa than in Southeast 
Asia where incidence is lower.
Decision makers are faced with selecting priority can-
cer control interventions unique to their setting, rec-
ognizing the heterogeneity of cancer burden according 
to region and the differing capacity of health systems. 
Context-specific expansion paths can help inform deci-
sion makers by facilitating a step-wise approach to the 
implementation of cancer control interventions. For 
example, this study demonstrates the importance in 
cost-effectiveness terms of ramping up treatment for 
the early stages of disease before progressing to system-
atic cancer screening programmes, an approach which 
is moreover consistent with existing WHO guidance, 
based on programmatic considerations [20]. For exam-
ple, in the expansion paths for both regions, treatment 
of breast cancer was found to be the most cost-effective 
breast cancer intervention, with compared to the null, 
an ICER of I$ 252 per HLY in southeast Asia (screening 
with mammography linked to timely diagnosis and treat-
ment has an ICER of I$ 1048 per HLY). Thus, a step-wise 
approach provides additional evidence in support of the 
view that expanding treatment services should gener-
ally be considered before introducing population-level 
screening programmes.
This study also highlights the importance of diagnos-
ing cancer early. Treatment for stage I colorectal cancer 
is approximately five times less expensive than treatment 
for stage II colorectal cancer. Furthermore, the impact 
of treatment is greater in stage I cancer as compared to 
stage II, III or IV [20, 42]. Accordingly, early diagnosis 
is particularly important to identify cancer at the stage 
when treatment is both more effective and less expen-
sive. Cancer control strategies that facilitate early diag-
nosis can provide a significant return on investment 
[20]. In combination with the previous paragraph, this 
implies that treatment services need to be expanded then 
screening introduced, and only when early diagnosis is 
achieved will the best value for money in cancer control 
be obtained.
Finally, it is important to note that while palliative care 
is not as cost-effective as other cancer control interven-
tion, it is an essential element of treatment, critical for 
human dignity, and it should be integrated into the con-
tinuum of care [38]. This study demonstrates that pal-
liative care programmes can be introduced at a relatively 
low cost and with minimal health system requirements. 
Table 4 Budgetary allocation among  cancers for  one country in  Southeast Asia and  Eastern sub-Saharan Africa 
for implementing the full expansion path at 95% coverage
Diseases Total costs (per 10 million population) Costs (%)
Southeast Asia Eastern sub-Saharan 
Africa
Southeast Asia Eastern 
sub-Saharan 
Africa
CVC 781,881,006 1,522,549,019 30 45
BRC 1,454,645,503 1,635,269,849 56 48
CRC 364,949,796 248,737,875 14 7
Total costs (per 10 million population) 2,601,476,305 3,406,556,743
Total undiscounted HLY (per 10 million population) 8,611,060 36,378,783
ACER 302.11 93.64
Total discounted HLY (per 10 million population) 1,830,047 4,938,728
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This cancer control element should be prioritized, par-
ticularly given that more than 80% of the global popula-
tion live in countries with low or non-existent access to 
adequate pain management [43].
Strengths of the analysis
The methodology presented in this study uses a com-
prehensive, health systems approach to cost-effective-
ness that considers diverse costs inputs including health 
workforce requirements, capital expenditures and con-
sumables informed by existing WHO guidance in can-
cer control, programmatic monitoring and evaluation 
costs and service delivery costs such as false positive 
results associated with cancer screening. By identifying 
and costing all identifiable inputs, this analysis calculates 
total costs including the costs of health system factors 
required for effective implementation.
For example, breast cancer screening considers a 
mechanism for call and recall of the population, diag-
nostic tests, false positive findings including subsequent 
diagnosis and pathology, diagnostic tests including 
immunohistochemistry for hormone receptor testing, 
staging for select individuals found to have cancer, health 
workforce time for treatment, management of treatment 
related toxicities, inpatient and outpatient costs, surveil-
lance after cancer treatment and monitoring and evalua-
tion of screening. Inclusion of these elements results in 
a more robust and accurate model, as each of them can 
contribute significantly to the costs of cancer screening 
and treatment programmes [32, 44, 45].
Additionally, a review of effect sizes utilized in previous 
analysis based on the study performed by Disease Con-
trol Priority, Volume 3, Cancer was made to ensure selec-
tion of effect sizes and methodology are consistent with 
the best available evidence [46].
Limitation of the analysis
There are six limitations to this analysis. First, while 
assumptions are based on best available evidence, there 
are gaps in high-quality evidence for cancer preven-
tion and control interventions. For example, because of 
its relatively recent introduction to the market, there is 
limited longitudinal data on the durability of HPV vac-
cination and its effect in protection against cervical can-
cer. Another example is to quantify the impact of surgery 
for stage I breast cancer compared to the null state of 
no treatment available. As would be expected, there is 
no randomized controlled trial evaluating the impact 
of this intervention. To mitigate the impact of this limi-
tation, assumptions were verified using available data 
such as historic publications and case series of patients 
who refuse treatment and/or aligned with previous 
assumptions in cancer cost-effectiveness studies; policy 
implications should be minor.
Second, there are insufficient studies for region- or 
country-specific variables. In this study, stage distribu-
tion, health workforce costs and programmatic costs 
were estimated based on available data. An assumption 
was made that the tumor biology/natural history of can-
cer was similar between settings. Additionally, the effect 
size of the intervention was used across all settings—that 
is, the impact of a particular intervention (e.g. vaccina-
tion, screening, treatment) was assumed to be equal in 
all setting. A literature review for region- or country-spe-
cific data was performed to address this limitation. How-
ever, there are limited data in low-resourced settings. 
Additional research is needed to develop regional specific 
inputs and variables; countries cannot generalize without 
regional or national epidemiologic data.
Third, the data used for the model were average 
regional estimates, as the scope of our work was gener-
alized analyses of the cost-effectiveness of interventions. 
Application of the model to individual countries should 
consider more country-specific data inputs as available, 
and conduct sensitivity analyses around the input param-
eters for evaluating the impact of parameter variabilities 
on program decisions.
Fourth, the disability weights used were from the 2010 
global burden diseases study. The development of the 
impact models began prior to the release of more recent 
disability weight data. As there has been minimal change 
in the disability weights for cancer stages in subsequent 
updates, and the costing baseline year is 2010, the authors 
were comfortable with continuing to use the 2010 esti-
mates which fall well within the uncertainty bounds of 
latter estimates.
Fifth, various models have been used for costing can-
cer control programmes, such as the bottom-up or top-
down method [47, 48]. Each strategy has advantages and 
disadvantages. In this study, the bottom-up approach 
was used, consistent with WHO-CHOICE methodology, 
allowing for comparison across diseases and settings. 
Furthermore, a thorough review of costing elements was 
considered to reduce any under-estimates. The GCEA 
is a standardized method for applying evidence to poor 
data settings where guidance is most needed. The tool 
has better use for priority setting than for budgeting. 
Results presented are intended to be indicative examples, 
rather than prescriptive packages or budgetary alloca-
tions for countries to implement. They must be evalu-
ated prospectively to correlate with budgets or National 
Health Accounts.
Finally, regarding the health outcomes model used the 
transition parameters were grouped according to general 
cancer types. Different cancer subtypes, such as hormone 
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receptor positive breast cancers, were not considered in 
this study. This model thus assumed that there is no sig-
nificant heterogeneity in the cancer subtypes between 
different populations.
Policy implications
The 2030 Agenda for Sustainable Development ushered 
in the era of universal health coverage (UHC) as a global 
priority. In order to achieve targets related to UHC, 
including financial protection, and reduce premature 
mortality from NCDs, a basic package of cancer services 
must be identified. Domestic, bilateral and multilateral 
funding should be channeled towards evidence-based, 
cost-effective interventions for cancer prevention and 
control, thereby avoiding unnecessary expenditure on 
high-cost interventions, medicines and technologies that 
yield less health benefit for populations [49]. This study 
provides the foundation for region-specific data to iden-
tify the most cost-effective cancer interventions that can 
be considered for inclusion in a basic package of cancer 
services.
Conclusion
This study presents the new WHO-CHOICE cost-
effectiveness results for three priority cancers, utilizing 
region-specific data to support decision-making based 
on epidemiologic profile, regional costs, and health sys-
tem capacity. The results demonstrate that cancer pre-
vention and control interventions are cost-effective and 
can be implemented through a step-wise approach to 
achieve maximum health benefits. As the global commu-
nity moves toward universal health coverage, this analysis 
can support decision makers in identifying a core pack-
age of cancer services, ensuring treatment and pallia-
tive care for all. Results are provided at regional level, an 
obvious contextualization is necessary for an individual 
country level implementation [50].
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